(13bR)-5,7&4,7-Dihydro-2,8-bis((tert-butyldimethylsilyl)oxy)-3H-cyclopenta[6,7]cycloocta[2,1-a:3,4-a']dinaphthalene

Inquiry
(13bR)-5,7&4,7-Dihydro-2,8-bis((tert-butyldimethylsilyl)oxy)-3H-cyclopenta[6,7]cycloocta[2,1-a:3,4-a']dinaphthalene is a chiral catalyst that has been intensively applied in asymmetric reactions with high atom economy.

Product Information

Purity
≥98%
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

(4R,5R)-1,3-dimethyl-4,5-diphenyl-2-[(S)-1-benzyl-2-hydroxyethylimidazolidine (CAS: 337308-63-1)
Palladium,[(1S)-[1,1'-binaphthalene]-2,2'-diylbis[diphenylphosphine-kP]]dichloro-, (SP-4-2)- (CAS: 127593-28-6)
(Diethylene) (13bS)-5,7-dihydro-2,8-dimethoxy-3H-cyclopenta[6,7]cycloocta[2,1-a:3,4-a']dinaphthalene Rhodium(I)
Chloro[(1,2,3,4,5-η)-1,2,3,4,5-pentamethyl-2,4-cyclopentadien-1-yl][2-(1,3-dioxoisoindolin-2-yl)-3,3-dimethyl-N-(quinolin-8-yl)butanamide]-Iridium
(Diethylene)(13bS)-7,13-Dimethoxy-1,2,3,4,10,12-hexahydro-8H-cyclopenta[5,6]cyclonona[1,2,3-cd:1,9,8-c'd']diindene Rhodium(I)
(4S,5S)-1,3-DIMETHYL-4,5-DIPHENYL-2-[(R)-1-BENZYL-2-HYDROXYETHYLIMINO]IMIDAZOLIDINE (CAS: 210468-90-9)
Our Services
Our Services

BOC Sciences leverages our expertise in asymmetric synthesis, chiral resolution and chiral analysis to support your research in chemical synthesis, drug development and analytical evaluation.

Learn More
Support Information
Support Information

Please click here to learn more about chiral technical support.

Learn More
Our Features

Suitable for your research and production needs. BOC Sciences provides the most comprehensive products and services. 24 hours customer support!

24 h
100%
Best
Global
Navigation
USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All rights reserved.